Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 15187 | 2.29 |
09:34 ET | 12800 | 2.28 |
09:36 ET | 600 | 2.28 |
09:38 ET | 3004 | 2.2599 |
09:39 ET | 7283 | 2.25 |
09:41 ET | 10017 | 2.25 |
09:45 ET | 100 | 2.255 |
09:48 ET | 400 | 2.255 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 766.6M | -1.1x | --- |
Erasca Inc | 771.2M | -2.8x | --- |
89Bio Inc | 783.7M | -3.6x | --- |
Rapport Therapeutics Inc | 749.1M | -11.5x | --- |
Replimune Group Inc | 748.8M | -3.3x | --- |
Arrivent Biopharma Inc | 789.3M | -9.3x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $766.6M |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 334.8M |
Nuvation Bio Inc does not pay a dividend. | |
Beta | 1.36 |
EPS | $-2.11 |
Book Value | $2.76 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 534.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,474.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.